18:30 , May 11, 2018 |  BC Week In Review  |  Clinical News

Bioniz reports Phase Ib data for T cell malignancies candidate

Bioniz Therapeutics Inc. (Irvine, Calif.) reported data from a single-blind, placebo-controlled, U.S. Phase Ib trial in 25 healthy volunteers showing that multiple ascending doses of T cell malignancies candidate BNZ-1 led to no serious adverse...
16:48 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Bioniz reports Phase I safety data for BNZ-1

Bioniz Therapeutics Inc. (Irvine, Calif.) reported data from a Phase I trial in 18 healthy volunteers showing that single ascending doses of T cell malignancies candidate BNZ-1 were well tolerated with no serious adverse events...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
20:34 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Rheumatoid arthritis (RA) Patient sample and mouse studies suggest promoting IL-9 secretion by type 2 innate lymphoid cells (ILC2s) could help treat RA. In RA patients receiving anti-inflammatory therapy, IL-9 secretion shifted from lymphoid...
07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

Cancer’s Phoenix

  Although recombinant IL-2 was a cancer immunotherapy long before checkpoint inhibitors came on the scene, the cytokine’s impact was limited by its potential for lethal side effects. Most attempts to lower toxicity also decreased...
07:00 , Aug 1, 2016 |  BC Extra  |  Financial News

Bioniz raises $13M in series A round

Bioniz Therapeutics Inc. (Irvine, Calif.) raised $13 million in a series A round co-led by the Takeda Ventures unit of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and David Pyott, the former chairman and CEO of Allergan...
07:00 , Oct 29, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interleukin-9 (IL-9); (FCER1A)

Inflammation INDICATION: Allergy Mouse studies suggest inhibiting the production of IL-9-producing mucosal mast cells (MMC9s) could help treat IgE-mediated food allergy. In a mouse model of food allergy, intragastric ovalbumin challenge increased numbers of intestinal...
07:00 , Jul 17, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Inflammatory bowel disease (IBD) IL-9 Studies in human samples and mice suggest antagonizing IL-9 could help treat IBD. In samples from patients with ulcerative...
08:00 , Feb 27, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer IL-9 In vitro and mouse studies suggest adoptive transfer of IL-9-producing T cells (Tc9) could help treat cancer. CD8+ T...
07:00 , Nov 1, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma IL-9 Mouse studies suggest IL-9-producing T helper type 9 (Th9) cells could help treat melanoma. In a mouse model of melanoma, an IL-9-neutralizing antibody...